article · Luminescence
This study introduces a novel approach for enhancing the inherent native fluorescence of pranoprofen, a nonsteroidal anti-inflammatory drug (NSAID), commonly used to treat allergic conjunctivitis. The fluorescence was significantly amplified when pranoprofen was encapsulated within the hydrophobic cavity of β-cyclodextrin, which provided a favorable microenvironment that stabilized its protonated form. The enhanced fluorescence intensity was measured at 404 nm following excitation at 273 nm with a large Stokes shift of around 130 nm. The method was validated following ICH guidelines and demonstrated excellent linearity over a concentration range of 0.10-6.0 μg/mL, with a correlation coefficient of 0.9999 and a low limit of detection (LOD) of 0.034 μg/mL. The proposed method was effectively applied for the analysis of pranoprofen in ophthalmic solutions and aqueous humor, yielding recoveries ranging from 98.9 to 101.1%. Furthermore, multifaceted sustainability assessment tools confirmed the method's eco-sustainability. This analytical strategy offers a reliable, rapid, and eco-friendly solution for the routine analysis of pranoprofen in pharmaceutical and clinical analysis.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1002/bio.70461
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.